BR9807486A - Epìtopos pre-m/m do vìrus da dengue, peptìdios, sintéticos, proteìnas quiméricas e uso das mesmas - Google Patents

Epìtopos pre-m/m do vìrus da dengue, peptìdios, sintéticos, proteìnas quiméricas e uso das mesmas

Info

Publication number
BR9807486A
BR9807486A BR9807486A BR9807486A BR9807486A BR 9807486 A BR9807486 A BR 9807486A BR 9807486 A BR9807486 A BR 9807486A BR 9807486 A BR9807486 A BR 9807486A BR 9807486 A BR9807486 A BR 9807486A
Authority
BR
Brazil
Prior art keywords
peptides
dengue virus
protein
epitopes
demonstrated
Prior art date
Application number
BR9807486A
Other languages
English (en)
Inventor
Susana Vazquez Ramudo
Guadalupe Guzman Tirado
Gerardo Enrique Guillen Nieto
Orlando Luis Pardo Lazo
Glay Chinea Santiago
Ana Beatriz Perez Diaz
Maritza Pupo Antunez
Rosmari Rodriguez Roche
Osvaldo Reyes Acosta
Cubana
Hilda Elisa Garay Perez
Gabriel Padron Palomares
Maylin Alvarez Vera
Luis Morier Diaz
Omaida Perez Insuita
Jose Luis Pelegrino Mar Cotera
Original Assignee
Cigb
Inst De Medicina Tropical Pedr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cigb, Inst De Medicina Tropical Pedr filed Critical Cigb
Publication of BR9807486A publication Critical patent/BR9807486A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Patente de Invenção: <B>"EPìTOPOS PRE-M/M DO VìRUSICAS E USO DAS MESMAS"<D>. A presente invenção refere-se a cinco peptídeos sintéticos da proteína pre-M/M do vírus de dengue 2, correspondentes às see 103-124. A resposta imunológica do antipeptídio combinantes também foram obtidas, incluindo regiões da proteína pre-M/M. A presença de epítopos de células B tanto como comundongos como em humanos foi demonstrada nos peptídeos da proteína pre-M/M. Orus da dengue. Respostas proliferativas específicas para vírus foram demonstradas em camundongos imunizados com os peptídios com os peptídios 3-31 e 57-92 não-conjugados. Camundongos imunizados com os peptídios 3-31, 57-92 e 69-93 conjugadores estavam protegidos quando receberam o virús da dengue 2. Assim, foi demonstrada a presença de epítopos seq³ênciais na proteína pre-M/M do vírus da dengue 2, assim como sua relevância na resposta imunológica contra este flavivírus.
BR9807486A 1997-01-15 1998-01-13 Epìtopos pre-m/m do vìrus da dengue, peptìdios, sintéticos, proteìnas quiméricas e uso das mesmas BR9807486A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU1997013A CU22683A1 (es) 1997-01-15 1997-01-15 Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
PCT/CU1998/000001 WO1998031814A1 (es) 1997-01-15 1998-01-13 Epitopes de la proteina pre-m/m del virus del dengue, peptidos sinteticos

Publications (1)

Publication Number Publication Date
BR9807486A true BR9807486A (pt) 2000-03-21

Family

ID=5459193

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807486A BR9807486A (pt) 1997-01-15 1998-01-13 Epìtopos pre-m/m do vìrus da dengue, peptìdios, sintéticos, proteìnas quiméricas e uso das mesmas

Country Status (15)

Country Link
US (1) US6383488B1 (pt)
EP (1) EP0966535B1 (pt)
JP (1) JP3647048B2 (pt)
CN (1) CN1198933C (pt)
AT (1) ATE284444T1 (pt)
AU (1) AU743414B2 (pt)
BR (1) BR9807486A (pt)
CA (1) CA2277816A1 (pt)
CU (1) CU22683A1 (pt)
DE (1) DE69828032T2 (pt)
ES (1) ES2235310T3 (pt)
HK (1) HK1025999A1 (pt)
MY (1) MY120971A (pt)
NO (1) NO993468L (pt)
WO (1) WO1998031814A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
KR101042458B1 (ko) * 2001-12-04 2011-06-16 벤처 테크놀로지스 에스디엔 비에이치디 플라비바이러스 ｎｓ1 서브유닛 백신
EP1454988A1 (en) * 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infectious flavivirus pseudo-particles containing functional prM-E envelope proteins
US7281274B2 (en) * 2003-10-16 2007-10-09 Lmp Media Llc Electronic media distribution system
WO2006025990A2 (en) * 2004-07-27 2006-03-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Diseases Control And Prevention Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
CU23578A1 (es) 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
WO2009024534A2 (en) * 2007-08-17 2009-02-26 Intercell Ag Japanese encephalitis virus (jev) and tick-borne encephalitis virus (tbev) peptides stimulating human t cell responses
CU20080028A6 (es) 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus
WO2010043977A2 (en) * 2008-10-13 2010-04-22 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
CN101921310B (zh) * 2009-06-15 2014-03-12 温州医学院 登革病毒特异性hla-a2限制性表位肽及应用
WO2011133112A1 (en) * 2010-04-20 2011-10-27 National University Of Singapore Cell penetrating peptide derived from the premembrane protein of flavivirus
BR112013030637A2 (pt) * 2011-05-26 2018-06-12 Inst De Medicina Molecular peptídeo derivado do vírus da dengue (denv) e métodos para a inibição da replicação de flavivírus
CU24188B1 (es) * 2012-12-27 2016-07-29 Ct De Ingeniería Genética Y Biotecnología Composición vacunal contra el virus dengue
US10053493B2 (en) * 2013-06-26 2018-08-21 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus vaccines
TWI769185B (zh) * 2016-10-27 2022-07-01 海樂源有限公司 登革熱類病毒顆粒、抗登革熱病毒抗體、及含其之組合物
CN116082499B (zh) * 2021-11-08 2023-10-27 东莞市朋志生物科技有限公司 一种抗登革ns1蛋白的抗体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040933A1 (en) * 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine

Also Published As

Publication number Publication date
AU5649998A (en) 1998-08-07
NO993468L (no) 1999-09-14
JP2001508457A (ja) 2001-06-26
CU22683A1 (es) 2001-07-20
CA2277816A1 (en) 1998-07-23
CN1249781A (zh) 2000-04-05
CN1198933C (zh) 2005-04-27
JP3647048B2 (ja) 2005-05-11
NO993468D0 (no) 1999-07-14
ES2235310T3 (es) 2005-07-01
DE69828032T2 (de) 2005-12-01
US6383488B1 (en) 2002-05-07
MY120971A (en) 2005-12-30
HK1025999A1 (en) 2000-12-01
ATE284444T1 (de) 2004-12-15
EP0966535A1 (en) 1999-12-29
WO1998031814A1 (es) 1998-07-23
DE69828032D1 (de) 2005-01-13
AU743414B2 (en) 2002-01-24
EP0966535B1 (en) 2004-12-08

Similar Documents

Publication Publication Date Title
BR9807486A (pt) Epìtopos pre-m/m do vìrus da dengue, peptìdios, sintéticos, proteìnas quiméricas e uso das mesmas
HK1022918A1 (en) Modified tnfalpha molecules, dna encoding such modified tnfalpha molecules and vaccines comprising such modified tnfalpha molecules and dna
EA199800946A1 (ru) Концентрированный препарат антител
ATE325882T1 (de) Polypeptide, die mit alfalfamosaikviralen oder ilarviralen kapsiden fusioniert sind
NO975435L (no) Modifiserte/kimeriske proteiner samt anvendelse derav
FI894065A0 (fi) Humanrhinovirusreceptorprotein som haemmar infektionsfoermaogan hos virus.
BR0107474A (pt) Preparação de proteìnas e permuteìnas desalergenizadas
EP0090581A3 (en) Small peptides with the specificity of foot and mouth disease viral antigens
ES2124922T3 (es) Peptidos derivados de un retrovirus del grupo hiv y su uso.
DE69535719D1 (de) Fas-antigenbindender ligand
Moore et al. Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats
ES2078971T3 (es) Produccion de virus y purificacion de proteinas con envoltura virica para uso en vacunas.
ATE382696T1 (de) Immunoreaktive antigene des hepatitis e viruses
PT1276763E (pt) Proteinas anti-congelantes sua producao e utilizacao
PT625157E (pt) Epitopes p1a1 e p1a2 da gpiiia da plaqueta sua preparacao e utilizacao
DE60131975D1 (de) Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
BR0212287A (pt) Proteìna de ligação caspase-8, sua preparação e uso
MY131433A (en) Novel metazoan parasite antigens having pepstatin binding activity and their use in vaccines
BR0010222A (pt) Vetores de expressão viral
WO2000061613A3 (en) Channel forming toxins as antiviral agents
WO1998042847A3 (de) Papillomvirus-hauptcapsid-proteins und deren verwendung in diagnose, therapie und vakzinierung
KR890009972A (ko) 펩티드, 이의 제조방법, 항체를 수득하기 위한 이의 용도, 및 인간 혈액중의 pai 1 활성을 억제하기 위한 항체의 용도
DE59509948D1 (de) Konjugat aus einem wirkstoff und einem nicht als körperfremd angesehenen, nativen protein
DE60122721D1 (de) Diagnostische verwendungen des t-zell proteins tzon7, der davon abgeleiteten peptide und des antikörpers
Tirrell Creating functional peptide architectures at interfaces

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements